Legal & General Group
ATRA icon

Legal & General Group’s Atara Biotherapeutics ATRA Stock Holding History

Legal & General Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-362
Closed -$6.28K – 3421
2024
Q1 		$6.28K Hold
362
– – ﹤0.01% 3270
2023
Q4 		$4.64K Hold
362
– – ﹤0.01% 3330
2023
Q3 		$13.4K Sell
362
-3,682
-91% -$164K ﹤0.01% 3192
2023
Q2 		$163K Buy
4,044
+3,438
+567% +$194K ﹤0.01% 2779
2023
Q1 		$44K Sell
606
-2,607
-81% -$253K ﹤0.01% 2898
2022
Q4 		$263K Hold
3,213
– – ﹤0.01% 2513
2022
Q3 		$304K Buy
3,213
+95
+3% +$10.7K ﹤0.01% 2472
2022
Q2 		$607K Buy
3,118
+76
+2% +$12.4K ﹤0.01% 2299
2022
Q1 		$707K Buy
3,042
+41
+1% +$13.1K ﹤0.01% 2310
2021
Q4 		$1.18M Buy
3,001
+690
+30% +$290K ﹤0.01% 2200
2021
Q3 		$1.03M Buy
2,311
+561
+32% +$201K ﹤0.01% 2241
2021
Q2 		$680K Sell
1,750
-57
-3% -$20.3K ﹤0.01% 2284
2021
Q1 		$649K Sell
1,807
-389
-18% -$172K ﹤0.01% 2266
2020
Q4 		$1.08M Buy
2,196
+712
+48% +$329K ﹤0.01% 2090
2020
Q3 		$481K Sell
1,484
-32
-2% -$10.9K ﹤0.01% 2204
2020
Q2 		$552K Buy
1,516
+100
+7% +$25.3K ﹤0.01% 2148
2020
Q1 		$302K Sell
1,416
-99
-7% -$31.4K ﹤0.01% 2194
2019
Q4 		$624K Buy
1,515
+677
+81% +$233K ﹤0.01% 2181
2019
Q3 		$296K Buy
838
+130
+18% +$48.5K ﹤0.01% 2272
2019
Q2 		$356K Buy
708
+28
+4% +$19.8K ﹤0.01% 2211
2019
Q1 		$675K Buy
680
+8
+1% +$7.43K ﹤0.01% 2089
2018
Q4 		$584K Buy
672
+39
+6% +$36.2K ﹤0.01% 2080
2018
Q3 		$655K Buy
633
+376
+146% +$368K ﹤0.01% 2073
2018
Q2 		$237K Buy
257
+9
+4% +$9.67K ﹤0.01% 2265
2018
Q1 		$243K Sell
248
-5
-2% -$4.56K ﹤0.01% 2259
2017
Q4 		$110K Sell
253
-27
-10% -$9.97K ﹤0.01% 2534
2017
Q3 		$115K Buy
280
+42
+18% +$15.8K ﹤0.01% 2570
2017
Q2 		$85K Hold
238
– – ﹤0.01% 2682
2017
Q1 		$120K Sell
238
-4
-2% -$1.66K ﹤0.01% 2448
2016
Q4 		$86K Buy
242
+99
+69% +$41.9K ﹤0.01% 2657
2016
Q3 		$75K Hold
143
– – ﹤0.01% 2327
2016
Q2 		$80K Buy
143
+44
+44% +$21.1K ﹤0.01% 2210
2016
Q1 		$49K Hold
99
– – ﹤0.01% 2420
2015
Q4 		$63K Hold
99
– – ﹤0.01% 2333
2015
Q3 		$82K Hold
99
– – ﹤0.01% 2153
2015
Q2 		$130K Buy
+99
New +$114K ﹤0.01% 1942

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Legal & General Group's ATRA Position: Q2 2024 in Review

Legal & General Group sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 362 shares — an estimated $6.28K sold.

Legal & General Group first reported a position in ATRA in Q2 2015 and held it in 36 quarters. The position peaked at $1.18M in Q4 2021. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Legal & General Group reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 362 Atara Biotherapeutics shares in Q2 2024, an estimated $6.28K.
  • Legal & General Group first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 36 quarters.
  • Legal & General Group's Atara Biotherapeutics position peaked at $1.18M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.